View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 29, 2020updated 12 Jul 2022 11:48am

PureTech to assess LYT-100 for Covid-19 respiratory complications

PureTech Health has plans to conduct a clinical trial to assess its LYT-100 (deupirfenidone) drug candidate to treat serious respiratory complications that persist even after resolution of Covid-19 infection.

PureTech Health has plans to conduct a clinical trial to assess its LYT-100 (deupirfenidone) drug candidate to treat serious respiratory complications that persist even after resolution of Covid-19 infection.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

A deuterated analogue of pirfenidone, LYT-100 exhibits anti-fibrotic and anti-inflammatory properties.

The drug candidate acts via a multimodal mechanism of action to potentially decrease, delay or prevent lung dysfunction that is known to occur in Covid-19 patients, including those who have recovered.

Expected to start in the third quarter of this year, the global, randomised, placebo-controlled trial will investigate the safety, efficacy and tolerability of LYT-100 in non-critical patients with respiratory complications.

The study is designed to enrol about 150 participants. Treatment duration is up to three months, with primary endpoint being pulmonary function testing.

In addition, the trial will evaluate exploratory endpoints, including pharmacokinetics, acute inflammatory biomarkers, hospitalisation events, imaging and patient-reported outcomes.Top-line data from the study are expected to be available next year.

PureTech R&D Committee member Dennis Ausiello said: “As we learn more about the full impact of Covid-19 on the body, we’re seeing post-recovery, longer-term pulmonary dysfunction similar to that observed following infection with other coronaviruses, including SARS and MERS.

“In fact, emerging data suggest that a high proportion of Covid-19 patients are at risk of impaired lung function and fibrosis after recovery, as well as during acute infection.

“With more than five million documented infections to date worldwide, there is a clear and urgent need for therapeutics to address the longer-term sequalae of Covid-19.”

In March this year, PureTech launched a Phase I trial to study the safety, tolerability and the pharmacokinetic profile of various LYT-100 doses in healthy participants. Results from this trial are set to be available later this year.

The company is also planning to initiate a subsequent proof-of-concept trial in patients with breast cancer-related, upper limb secondary lymphoedema, as well as evaluate the drug candidate to treat other inflammatory and fibrotic conditions.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena